Xiawei Wei

21.1k total citations · 17 hit papers
190 papers, 12.9k citations indexed

About

Xiawei Wei is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Xiawei Wei has authored 190 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Molecular Biology, 61 papers in Immunology and 34 papers in Oncology. Recurrent topics in Xiawei Wei's work include SARS-CoV-2 and COVID-19 Research (26 papers), Immune cells in cancer (25 papers) and RNA Interference and Gene Delivery (23 papers). Xiawei Wei is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (26 papers), Immune cells in cancer (25 papers) and RNA Interference and Gene Delivery (23 papers). Xiawei Wei collaborates with scholars based in China, United States and United Kingdom. Xiawei Wei's co-authors include Yuquan Wei, Xuelei Ma, Weiqi Hong, Manni Wang, Yong Peng, Ji Nie, Jing Yang, Tianxia Lan, Yuan Cheng and Zhiyong Qian and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Xiawei Wei

185 papers receiving 12.7k citations

Hit Papers

Targeting PI3K in cancer: mechanisms and advances in clin... 2019 2026 2021 2023 2019 2019 2022 2022 2019 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting PI3K in cancer: mechanisms and advances in clinical trials
    2019 1.1k citations Xuelei Ma, Yuquan Wei et al. profile →
  2. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
    2019 735 citations He Cai, Xuelei Ma et al. Signal Transduction and Targeted Therapy profile →
  3. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
    2022 560 citations Weiqi Hong, Xiawei Wei et al. profile →
  4. Cancer vaccines as promising immuno-therapeutics: platforms and current progress
    2022 473 citations Dandan Wan, Yuquan Wei et al. profile →
  5. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
    2019 359 citations Yuquan Wei, Xiawei Wei et al. profile →
  6. SARS‐CoV‐2 Omicron variant: Characteristics and prevention
    2021 351 citations Xuemei He, Weiqi Hong et al. SHILAP Revista de lepidopterología profile →
  7. Cellular Toxicity and Immunological Effects of Carbon-based Nanomaterials
    2019 332 citations Yuquan Wei, Xiawei Wei et al. profile →
  8. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
    2022 331 citations Yuquan Wei, Xiawei Wei et al. profile →
  9. mRNA vaccine: a potential therapeutic strategy
    2021 286 citations Yuquan Wei, Xiawei Wei et al. profile →
  10. Mesenchymal stem/stromal cells in cancer therapy
    2021 225 citations Tianxia Lan, Min Luo et al. profile →
  11. Role of lysosomes in physiological activities, diseases, and therapy
    2021 216 citations Yuquan Wei, Xiawei Wei et al. profile →
  12. Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting
    2021 213 citations Yuquan Wei, Xiawei Wei et al. profile →
  13. CCL5/CCR5 axis in human diseases and related treatments
    2021 201 citations Tianxia Lan, Yuquan Wei et al. profile →
  14. Targeting the tumor stroma for cancer therapy
    2022 175 citations Yuquan Wei, Xiawei Wei et al. profile →
  15. Intranasal COVID-19 vaccines: From bench to bed
    2022 162 citations Aqu Alu, Lei Hong et al. profile →
  16. Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
    2024 127 citations Xiawei Wei et al. profile →
  17. The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
    2023 82 citations Danyi Ao, Xuemei He et al. SHILAP Revista de lepidopterología profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiawei Wei China 56 5.9k 3.1k 2.8k 1.8k 1.5k 190 12.9k
Mehdi Yousefi Iran 61 4.9k 0.8× 3.3k 1.1× 1.4k 0.5× 1.4k 0.8× 1.5k 1.0× 393 13.3k
Yang Cao China 64 5.8k 1.0× 2.0k 0.6× 1.7k 0.6× 2.6k 1.4× 2.0k 1.3× 653 17.4k
Min Wu China 59 7.4k 1.3× 1.8k 0.6× 1.0k 0.4× 1.6k 0.9× 1.2k 0.8× 378 14.2k
Behzad Baradaran Iran 70 11.7k 2.0× 3.3k 1.1× 4.1k 1.4× 3.2k 1.8× 5.3k 3.4× 648 21.2k
Jianhua Yu United States 71 6.3k 1.1× 6.9k 2.2× 5.5k 1.9× 1.6k 0.9× 2.3k 1.5× 308 16.5k
Chris Reutelingsperger Netherlands 60 9.4k 1.6× 4.7k 1.5× 1.3k 0.5× 1.1k 0.6× 1.4k 0.9× 260 18.4k
Man Li China 56 3.8k 0.6× 1.8k 0.6× 1.9k 0.7× 2.2k 1.2× 1.0k 0.7× 354 9.8k
Dmitri V. Krysko Belgium 53 6.6k 1.1× 5.3k 1.7× 2.7k 1.0× 3.5k 1.9× 1.7k 1.1× 124 15.1k
Hamed Mirzaei Iran 79 10.3k 1.7× 1.9k 0.6× 1.7k 0.6× 1.3k 0.7× 6.4k 4.2× 359 17.9k
Changyi Chen United States 64 5.2k 0.9× 1.8k 0.6× 1.9k 0.7× 858 0.5× 1.7k 1.1× 283 14.0k

Countries citing papers authored by Xiawei Wei

Since Specialization
Citations

This map shows the geographic impact of Xiawei Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiawei Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiawei Wei more than expected).

Fields of papers citing papers by Xiawei Wei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiawei Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiawei Wei. The network helps show where Xiawei Wei may publish in the future.

Co-authorship network of co-authors of Xiawei Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Xiawei Wei. A scholar is included among the top collaborators of Xiawei Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiawei Wei. Xiawei Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ao, Danyi, Dandan Peng, Cai He, et al.. (2025). A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants. Molecular Biomedicine. 6(1). 13–13. 2 indexed citations
2.
Wan, Dandan, Liang Yu, Li Chen, et al.. (2024). Simultaneous enhancement of cellular and humoral immunity by the lymph node-targeted cholesterolized TLR7 agonist liposomes. Acta Pharmaceutica Sinica B. 14(10). 4577–4590. 4 indexed citations
3.
4.
Hong, Lei, Aqu Alu, H. J. Yang, et al.. (2023). Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants. Nature Communications. 14(1). 2678–2678. 30 indexed citations
5.
He, Cai, Aqu Alu, Lei Hong, et al.. (2023). A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2. SHILAP Revista de lepidopterología. 4(3). e263–e263. 11 indexed citations
6.
Liu, Jian, et al.. (2023). Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development. Vaccines. 11(7). 1218–1218. 33 indexed citations
7.
Yang, H. J., Weiqi Hong, Lei Hong, et al.. (2023). Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection. Signal Transduction and Targeted Therapy. 8(1). 252–252. 20 indexed citations
8.
Chang, Shenghai, Qinghua Luo, Chun Chan, et al.. (2023). Structural basis of BAM-mediated outer membrane β-barrel protein assembly. Nature. 617(7959). 185–193. 38 indexed citations
9.
Zhao, Jie, Hong Fu, Jingjing Yu, et al.. (2023). Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine. Nature Communications. 14(1). 962–962. 21 indexed citations
10.
Hong, Lei, Aqu Alu, H. J. Yang, et al.. (2022). Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants. Signal Transduction and Targeted Therapy. 7(1). 159–159. 31 indexed citations
11.
Lan, Tianxia, Ting Liu, Bin Shao, et al.. (2022). CXCL13 as a Novel Immune Checkpoint for Regulatory B Cells and Its Role in Tumor Metastasis. The Journal of Immunology. 208(10). 2425–2435. 22 indexed citations
12.
Liang, Xiao, Min Luo, Bin Shao, et al.. (2022). Phosphatidylserine released from apoptotic cells in tumor induces M2‐like macrophage polarization through the PSR‐STAT3‐JMJD3 axis. Cancer Communications. 42(3). 205–222. 39 indexed citations
13.
Chen, Feng, Jianbo Li, Xiefang Yuan, et al.. (2021). Novel Lytic Phages Protect Cells and Mice against Pseudomonas aeruginosa Infection. Journal of Virology. 95(8). 30 indexed citations
14.
Tang, Xiaodi, Shenghai Chang, Ke Zhang, et al.. (2021). Structural basis for bacterial lipoprotein relocation by the transporter LolCDE. Nature Structural & Molecular Biology. 28(4). 347–355. 47 indexed citations
15.
Chen, Yuwen, Jiumeng Zhang, Xuan Liu, et al.. (2020). Noninvasive in vivo 3D bioprinting. Science Advances. 6(23). eaba7406–eaba7406. 256 indexed citations
16.
Luo, Min, Zhipeng Meng, Toshiro Moroishi, et al.. (2020). Publisher Correction: Heat stress activates YAP/TAZ to induce the heat shock transcriptome. Nature Cell Biology. 23(2). 209–209. 2 indexed citations
17.
Tang, Xiaodi, Shenghai Chang, Qiao Wen, et al.. (2020). Structural insights into outer membrane asymmetry maintenance in Gram-negative bacteria by MlaFEDB. Nature Structural & Molecular Biology. 28(1). 81–91. 63 indexed citations
18.
Chen, Piaopiao, Ke Huang, Rui Dai, et al.. (2019). Sensitive CVG-AFS/ICP-MS label-free nucleic acid and protein assays based on a selective cation exchange reaction and simple filtration separation. The Analyst. 144(8). 2797–2802. 21 indexed citations
19.
Chen, Piaopiao, Xin Jiang, Ke Huang, et al.. (2019). Multimode MicroRNA Sensing via Multiple Enzyme-Free Signal Amplification and Cation-Exchange Reaction. ACS Applied Materials & Interfaces. 11(40). 36476–36484. 52 indexed citations
20.
Chen, Piaopiao, Pingyue Hu, Ke Huang, et al.. (2018). Detection of nucleic acids via G-quadruplex-controlled l-cysteine oxidation and catalyzed hairpin assembly-assisted signal amplification. RSC Advances. 8(71). 40564–40569. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mehdi Yousefi Breakdown of academic impact, for papers by Yang Cao Breakdown of academic impact, for papers by Min Wu Breakdown of academic impact, for papers by Behzad Baradaran Breakdown of academic impact, for papers by Jianhua Yu Breakdown of academic impact, for papers by Chris Reutelingsperger Breakdown of academic impact, for papers by Man Li Breakdown of academic impact, for papers by Dmitri V. Krysko Breakdown of academic impact, for papers by Hamed Mirzaei Breakdown of academic impact, for papers by Changyi Chen
Rankless by CCL
2026